In the manuscript “The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study,” authors noted a minor error in the plot headings for Fig. 3, panels A and B. Figure 3A should read “Route of administration: IV,” and Fig. 3B should read “Route of administration: SC,” as per the Fig. 3 legend. The PDF and HTML (full text) have been corrected.
- Copyright © 2017, American Association for the Advancement of Science
